AFLIBERCEPT IN AMD: OUR EXPERIENCE IN THE TREATMENT OF RESISTANT OR RECURRENT PATIENTS

J. Lemos, C. Teixeira, J. Martins, C. Menezes
Department of Ophthalmology, Hospital Pedro Hispano, Portugal

Purpose: to report aflibercept results in patients with resistant or recurrent AMD, who have been treated with others anti-VEGF. Methods: a review of 16 patients (17 eyes) with resistant or recurrent wet AMD that started aflibercept treatment after doing several injections of another anti-VEGF. All enrolled patients medical records were retrospectively reviewed for age, gender, previous treatments, best corrected visual acuity (BCVA) at baseline and at 1, 3, 6 and 9 months and pre and post-treatment OCT features. Results: 8 male and 8 female patients, with an average age of 75 years (61-86). The mean number of previous anti-VEGF injections was 13 and almost all cases were treated with ranibizumab. In several patients (11), the eye in study was the only seeing Eye. In the majority of eyes, the retinal fluid resolved completely, EPR detachments diminished in size and BCVA remained stable or suffered an improvement. Conclusion: aflibercept is an effective treatment of patients with persistent or recurrent retinal fluid and RPE detachments after several injections of other anti-VEGF agents.